3 results
Approved WMOCompleted
Correcting the causative factors of intertrigo is critical. Take steps to eliminate friction, heat, and maceration by keeping folds cool and dry. The goals of pharmacotherapy for intertrigo are to reduce morbidity and to prevent complications. To…
Approved WMOWill not start
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with RR DLBCL, including those with MYC Alterations.
Approved WMOCompleted
To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…